KILITCH.NS实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 17:59):

Stats
今日成交量	3 862.00
平均成交量	10 341.00
市值	5.55B
EPS	INR0 ( 2024-02-08 )
下一个收益日期	( INR0 ) 2024-05-27
Last Dividend	INR0.500 ( 2019-09-20 )
Next Dividend	INR0 ( N/A )
P/E	37.36
ATR14	INR1.193 (0.35%)

音量相关性

長: -0.32 (neutral)

短: 0.25 (neutral)

Signal:(44.925) Neutral

Kilitch Drugs (India) 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Kilitch Drugs (India) 相关性 - 货币/商品

-0.49
( neutral )

0.40
( neutral )

-0.78
( moderate negative )

0.03
( neutral )

-0.38
( neutral )

0.82
( strong )

Kilitch Drugs (India) 财务报表

Annual	2022
营收:	INR1.40B
毛利润:	INR648.40M (46.45 %)
EPS:	INR6.71

FY	2022
营收:	INR1.40B
毛利润:	INR648.40M (46.45 %)
EPS:	INR6.71

FY	2022
营收:	INR1.14B
毛利润:	INR488.01M (42.72 %)
EPS:	INR4.73

FY	2021
营收:	INR685.23M
毛利润:	INR312.16M (45.56 %)
EPS:	INR2.37

Financial Reports:

No articles found.

Kilitch Drugs (India) Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Kilitch Drugs (India) Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 3.63 - low (20.78%) | Divividend Growth Potential Score: 3.46 - No dividend growth expected in the near future

Information

First Dividend	INR1.000	2010-10-14
Last Dividend	INR0.500	2019-09-20
Next Dividend	INR0	N/A
Payout Date	2019-10-30
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	INR33.00	--
Avg. Dividend % Per Year	0.00%	--
Score	1.31	--
Div. Sustainability Score	3.63
Div.Growth Potential Score	3.46
Div. Directional Score	3.55	--

Next Divdend (Est)
(2025-09-01)

INR0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

1.31

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.500	0.59%
2019	INR0.500	0.31%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
PSB.NS	No Dividend Player	2023-07-04	Sporadic	14	0.77%
KCP.NS	Dividend Junior	2023-08-10	Annually	23	0.55%
EIMCOELECO.NS	Dividend Knight	2023-06-16	Annually	23	0.80%
AGARIND.NS	Ex Dividend Junior	2023-09-08	Annually	11	0.44%
SUMICHEM.NS	Dividend Junior	2023-07-20	Annually	5	0.17%
NATCOPHARM.NS	Dividend Junior	2023-08-22	Semi-Annually	29	0.68%
HITECHCORP.NS	Dividend Junior	2023-06-30	Annually	17	0.30%
CANBK.NS	Dividend Junior	2023-06-14	Sporadic	22	1.58%
RICOAUTO.NS	Dividend Junior	2023-09-22	Annually	22	0.54%
L&TFH.NS	Dividend Junior	2023-07-21	Annually	12	0.77%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0940	1.500	8.12	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.0916	1.500	-0.0933	-0.140	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	4.20	1.000	9.56	9.56	[3 - 30]
operatingCashFlowPerShareTTM	4.15	2.00	8.62	10.00	[0 - 30]
freeCashFlowPerShareTTM	4.15	2.00	7.93	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.486	1.000	5.24	5.24	[0.2 - 0.8]
operatingProfitMarginTTM	0.158	1.000	8.85	8.85	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.63

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	38.79	1.000	6.18	0	[1 - 100]
returnOnEquityTTM	0.0916	2.50	-0.0600	-0.140	[0.1 - 1.5]
freeCashFlowPerShareTTM	4.15	2.00	8.62	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	4.15	2.00	8.62	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.927	1.500	7.16	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0430	1.000	-1.424	0	[0.1 - 0.5]
Total Score				3.46

Kilitch Drugs (India)

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrups, gripe water, and oral powders and liquids in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.